Activation of PPARγ by pioglitazone does not attenuate left ventricular hypertrophy following aortic banding in rats

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 381, Issue 4, 2010, Pages 285-295

  Weiss, Celine S ^a   Hagenmüller, Marco ^a   Pichler, Martina ^a   Münz, Sebastian ^a   Ochs, Marco ^a   Buss, Sebastian J ^a   Bekeredjian, Raffi ^a   Katus, Hugo A ^a   Hardt, Stefan E ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Aortic banding; Cardiac remodeling; Left ventricular hypertrophy; Pioglitazone; PPAR

Indexed keywords

ATRIAL NATRIURETIC FACTOR; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA BANDING; ARTERY LIGATION; ARTICLE; ASCENDING AORTA; CELL SIZE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; GENE EXPRESSION; GENE LOCATION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE PRESSURE; HISTOPATHOLOGY; MALE; NONHUMAN; RAT; SHAM PROCEDURE; TRANSCRIPTION INITIATION; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY; THORACIC AORTA; WISTAR RAT;

ANIMALS; AORTA, THORACIC; ATRIAL NATRIURETIC FACTOR; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; HYPERTROPHY, LEFT VENTRICULAR; HYPOGLYCEMIC AGENTS; MALE; MYOCYTES, CARDIAC; PPAR GAMMA; RATS; RATS, WISTAR; THIAZOLIDINEDIONES; VENTRICULAR FUNCTION, LEFT;

EID: 77953230369     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-009-0488-7     Document Type: Article

References (37)

1. K Arakawa T Ishihara M Aoto M Inamasu K Kitamura A Saito 2004 An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats Clin Exp Pharmacol Physiol 31 8 13 10.1111/j.1440-1681. 2004.03954.x 14756678 1:CAS:528:DC%2BD2cXhs1Chtro%3D (Pubitemid 38230742)
2. M Asakawa H Takano T Nagai H Uozumi H Hasegawa, et al. 2002 Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo Circulation 105 1240 1246 10.1161/hc1002.105225 11889020 1:CAS:528:DC%2BD38XivFaqur0%3D (Pubitemid 34225827)
3. P Balakumar M Singh 2006 Possible role of poly(ADP-ribose) polymerase in pathological and physiological cardiac hypertrophy Methods Find Exp Clin Pharmacol 28 683 689 10.1358/mf.2006.28.10.1037495 17235412 1:CAS:528: DC%2BD2sXis1Omu74%3D (Pubitemid 46230792)
4. D Bell BJ McDermott 2005 Effects of rosiglitazone and interactions with growth-regulating factors in ventricular cell hypertrophy Eur J Pharmacol 508 69 76 10.1016/j.ejphar.2004.12.027 15680255 1:CAS:528:DC%2BD2MXmvFyqtw%3D%3D (Pubitemid 40169903)
5. D Bishop-Bailey 2000 Peroxisome proliferator-activated receptors in the cardiovascular system Br J Pharmacol 129 823 834 10.1038/sj.bjp.0703149 10696077 1:CAS:528:DC%2BD3cXhvVemu78%3D
6. Z Chen S Ishibashi S Perrey J Osuga T Gotoda, et al. 2001 Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL Arterioscler Thromb Vasc Biol 21 372 377 11231916 1:CAS:528:DC%2BD3MXhvVyrsbw%3D
7. AR Collins WP Meehan U Kintscher S Jackson S Wakino, et al. 2001 Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice Arterioscler Thromb Vasc Biol 21 365 371 11231915 1:CAS:528:DC%2BD3MXhvVyrsb4%3D
8. SZ Duan CY Ivashchenko MW Russell DS Milstone RM Mortensen 2005 Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice Circ Res 97 372 379 10.1161/01.RES.0000179226.34112.6d 16051889 1:CAS:528:DC%2BD2MXntlSiurg%3D (Pubitemid 41216142)
9. L Fajas D Auboeuf E Raspe K Schoonjans AM Lefebvre, et al. 1997 The organization, promoter analysis, and expression of the human PPARgamma gene J Biol Chem 272 18779 18789 10.1074/jbc.272.30.18779 9228052 1:CAS:528: DyaK2sXltVSgs74%3D (Pubitemid 27318225)
10. WT Festuccia M Laplante S Brule VP Houde A Achouba, et al. 2009 Rosiglitazone-induced heart remodelling is associated with enhanced turnover of myofibrillar protein and mTOR activation J Mol Cell Cardiol 47 85 95 10.1016/j.yjmcc.2009.04.011 19397913 1:CAS:528:DC%2BD1MXms1Ortrc%3D
11. DF Geng W Wu DM Jin JF Wang YM Wu 2006 Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction Int J Cardiol 113 86 91 10.1016/j.ijcard.2006.03.060 16891009 (Pubitemid 44648366)
12. MN Ghazzi JE Perez TK Antonucci JH Driscoll SM Huang, et al. 1997 Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group Diabetes 46 433 439 10.2337/diabetes.46.3.433 9032099 1:CAS:528:DyaK2sXhsVGlur0%3D
13. RB Goldberg DM Kendall MA Deeg JB Buse AJ Zagar, et al. 2005 A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia Diabetes Care 28 1547 1554 10.2337/diacare.28.7.1547 15983299 1:CAS:528:DC%2BD2MXms12ntLk%3D (Pubitemid 40923063)
14. Y Guan C Hao DR Cha R Rao W Lu, et al. 2005 Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption Nat Med 11 861 866 10.1038/nm1278 16007095 1:CAS:528: DC%2BD2MXmvFemsLY%3D (Pubitemid 41161118)
15. T Horio M Suzuki K Suzuki I Takamisawa A Hiuge, et al. 2005 Pioglitazone improves left ventricular diastolic function in patients with essential hypertension Am J Hypertens 18 949 957 10.1016/j.amjhyper.2005.02.003 16053992 1:CAS:528:DC%2BD2MXmvVGju7k%3D (Pubitemid 41040266)
16. A Hsiao DS Worrall JM Olefsky S Subramaniam 2004 Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes Bioinformatics 20 3108 3127 10.1093/bioinformatics/bth371 15217816 1:CAS:528:DC%2BD2cXhtVSrur3N (Pubitemid 39619201)
17. H Ito A Nakano M Kinoshita A Matsumori 2003 Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model Lab Invest 83 1715 1721 10.1097/01.LAB.0000106724.29121.DA 14691289 1:CAS:528:DC%2BD3sXpsl2msL8%3D (Pubitemid 38018534)
18. M Iwase SP Bishop M Uechi DE Vatner RP Shannon, et al. 1996 Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression Circ Res 78 517 524 8635208 1:CAS:528:DyaK28XhvVynur4%3D
19. D Levy RJ Garrison DD Savage WB Kannel WP Castelli 1990 Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study N Engl J Med 322 1561 1566 2139921 1:STN:280: DyaK3c3ksFSmug%3D%3D
20. AC Li KK Brown MJ Silvestre TM Willson W Palinski CK Glass 2000 Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice J Clin Invest 106 523 531 10.1172/JCI10370 10953027 1:CAS:528:DC%2BD3cXlvFCltbk%3D
21. R Marfella M D'Amico K Esposito A Baldi C Di Filippo, et al. 2006 The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment Diabetes 55 622 632 10.2337/diabetes.55.03.06.db05-0832 16505224 1:CAS:528:DC%2BD28XisVWisrk%3D
22. J Minamikawa S Tanaka M Yamauchi D Inoue H Koshiyama 1998 Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes J Clin Endocrinol Metab 83 1818 1820 10.1210/jc.83.5.1818 9589700 1:CAS:528:DyaK1cXjtF2gsbs%3D (Pubitemid 28501066)
23. RW Nesto D Bell RO Bonow V Fonseca SM Grundy, et al. 2003 Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003 Circulation 108 2941 2948 10.1161/01.CIR. 0000103683.99399.7E 14662691 (Pubitemid 37517824)
24. SE Nissen K Wolski 2007 Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2457 2471 10.1056/NEJMoa072761 17517853 1:CAS:528:DC%2BD2sXms1SisrY%3D
25. JM Olefsky 2000 Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists J Clin Invest 106 467 472 10.1172/JCI10843 10953021 1:CAS:528:DC%2BD3cXlvFCltb8%3D
26. LC Pickavance M Tadayyon PS Widdowson RE Buckingham JP Wilding 1999 Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution Br J Pharmacol 128 1570 1576 10.1038/sj.bjp.0702932 10602338 1:CAS:528:DyaK1MXotFSit78%3D
27. R Qayyum P Schulman 2006 Cardiovascular effects of the thiazolidinediones Diabetes Metab Res Rev 22 88 97 10.1002/dmrr.596 16184618 1:CAS:528: DC%2BD28XjsFagtro%3D
28. SM Rangwala MA Lazar 2004 Peroxisome proliferator-activated receptor gamma in diabetes and metabolism Trends Pharmacol Sci 25 331 336 10.1016/j.tips.2004.03.012 15165749 1:CAS:528:DC%2BD2cXksVelsLk%3D (Pubitemid 38692426)
29. M Rose P Balakumar M Singh 2007 Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats Pharmacology 80 177 184 10.1159/000103917 17570955 1:CAS:528: DC%2BD2sXos1Kntb0%3D (Pubitemid 47230712)
30. S Sakai T Miyauchi Y Irukayama-Tomobe T Ogata K Goto I Yamaguchi 2002 Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats Clin Sci (Lond) 103 Suppl 48 16S 20S 1:CAS:528:DC%2BD38XotFKht7s%3D
31. S Sena IR Rasmussen AR Wende AP McQueen HA Theobald, et al. 2007 Cardiac hypertrophy caused by peroxisome proliferator- activated receptor-gamma agonist treatment occurs independently of changes in myocardial insulin signaling Endocrinology 148 6047 6053 10.1210/en.2006-1559 17823261 1:CAS:528: DC%2BD2sXhsVers73L (Pubitemid 350146163)
32. T Shiomi H Tsutsui S Hayashidani N Suematsu M Ikeuchi, et al. 2002 Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction Circulation 106 3126 3132 10.1161/01.CIR.0000039346.31538.2C 12473562 (Pubitemid 35440299)
33. NH Son TS Park H Yamashita M Yokoyama LA Huggins, et al. 2007 Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice J Clin Invest 117 2791 2801 10.1172/JCI30335 17823655 1:CAS:528:DC%2BD2sXhtFCnt73P (Pubitemid 47529610)
34. K Yamamoto R Ohki RT Lee U Ikeda K Shimada 2001 Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes Circulation 104 1670 1675 10.1161/hc4001.097186 11581147 1:CAS:528:DC%2BD3MXotVehtLg%3D
35. Z Yuan Y Liu J Zhang C Kishimoto Y Wang, et al. 2003 Peroxisome proliferation-activated receptor-gamma ligands ameliorate experimental autoimmune myocarditis Cardiovasc Res 59 685 694 10.1016/S0008-6363(03)00457-7 14499870 1:CAS:528:DC%2BD3sXnt1Glurg%3D (Pubitemid 38368685)
36. TL Yue Tl J Chen W Bao PK Narayanan A Bril, et al. 2001 In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone Circulation 104 2588 2594 10.1161/hc4601.099403 11714655 1:STN:280:DC%2BD3MnmvVOksw%3D%3D
37. H Zhang A Zhang DE Kohan RD Nelson FJ Gonzalez T Yang 2005 Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention Proc Natl Acad Sci U S A 102 9406 9411 10.1073/pnas.0501744102 15956187 1:CAS:528:DC%2BD2MXlvF2rsb4%3D (Pubitemid 40923576)